China's Epilepsy Market Growing Rapidly; Attracting More Multinational Companies
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The Chinese anti-epilepsy drug market is expected to grow at an annual rate of roughly 30 percent in coming years, and multinational companies account for most of that market share, healthcare analysts predict
You may also be interested in...
UCB’s Vimpat Gets FDA Approval For Epileptic Seizures
Belgian specialty pharma hopes to launch drug in U.S. early next year; says blockbuster sales could follow.
NovaMed CEO Mark Lotter On Working With Pharma Distributors In China: An Interview With PharmAsia News
Shanghai-based NovaMed Pharmaceuticals was founded in August 2005 to provide distribution services for multinational pharmaceutical companies in China. NovaMed has signed China deals with several multinationals, including Baxter, Pfizer and Sanofi-Aventis. NovaMed Founder and CEO Mark Lotter recently participated in an email interview with PharmAsia News' Shanghai bureau about the changing contours of the pharmaceutical sector in China.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).